Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Liabilities and Shareholders Equity (2024 - 2025)

Prelude Therapeutics (PRLD) has disclosed Liabilities and Shareholders Equity for 2 consecutive years, with $141.3 million as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity fell 19.49% to $141.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $492.2 million through Dec 2025, down 41.69% year-over-year, with the annual reading at $141.3 million for FY2025, 19.49% down from the prior year.
  • Liabilities and Shareholders Equity hit $141.3 million in Q4 2025 for Prelude Therapeutics, up from $94.8 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $247.1 million in Q1 2024 to a low of $94.8 million in Q3 2025.